| P2093 | author name string | Roodman GD | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 |
| | Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease | Q62003041 |
| | Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption | Q67602665 |
| | Bone scintigraphy in the diagnosis of skeletal involvement and metastatic calcification in multiple myeloma | Q70442702 |
| | Cytokines involved in the progression of multiple myeloma | Q70646343 |
| | Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma | Q74344629 |
| | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 |
| | Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis | Q79326661 |
| | MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma | Q79930079 |
| | Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment | Q80146976 |
| | Fracture risk with multiple myeloma: a population-based study | Q81476638 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro | Q24675778 |
| | The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 |
| | RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 |
| | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells | Q28591227 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 |
| | Mechanisms of bone metastasis | Q33977526 |
| | Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease | Q34182154 |
| | RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 |
| | Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo | Q35642745 |
| | Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects | Q36083211 |
| | Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma | Q36561970 |
| | Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. | Q36569101 |
| | Response to bortezomib and activation of osteoblasts in multiple myeloma | Q36616740 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation | Q38325516 |
| | MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells | Q40221732 |
| | Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction | Q40311674 |
| | IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma | Q40425654 |
| | MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. | Q40454635 |
| | Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. | Q40538587 |
| | Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma | Q40608447 |
| | IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells | Q40616669 |
| | Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases | Q43563141 |
| | Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity | Q43883711 |
| | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index | Q44032751 |
| | Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells | Q44265469 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Cancer and the microenvironment: myeloma-osteoclast interactions as a model | Q44802876 |
| | Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. | Q46283393 |
| | Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid | Q46570802 |
| | Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. | Q46864843 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion | Q47371978 |
| | Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia | Q47397528 |
| | Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma | Q47965350 |
| | Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. | Q48020559 |
| | Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease | Q48022318 |
| | Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. | Q50948835 |
| | Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. | Q51231723 |
| | Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. | Q51802618 |
| | SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. | Q53589040 |
| | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease | Q57374932 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1139-1146 | |
| P577 | publication date | 2007-08-06 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Treatment strategies for bone disease | |
| P478 | volume | 40 | |